Discover Milestone Scientific's Q4 2025 earnings call highlights, including financial performance, strategic initiatives, and future outlook.

Milestone Scientific, Inc. reported its fourth quarter 2025 financial results, showcasing a strategic restructuring and a renewed focus on growth. Under the leadership of CEO Eric Hines, who took the helm in August 2025, the company is poised for significant improvement with targeted investments and a clearer operational model. Key takeaways from the call reflect a commitment to responsible financial stewardship and an optimistic outlook for 2026.

Financial Performance

In the fourth quarter of 2025, Milestone Scientific achieved total revenue of $2.1 million, representing a 2.2% increase from $2 million in the same period in 2024. This growth is attributed primarily to increased sales in the company's dental segment. Despite maintaining a gross profit of $1.5 million, the operating loss improved significantly to $1.1 million, an 89% reduction from the $2 million loss reported in the prior year. The net loss for Q4 2025 also decreased to $1.1 million, down from $2 million in 2024.

For the full year, Milestone Scientific reported net sales totaling $9 million, a 4% increase from $8.6 million in 2024. The gross profit remained stable at $6.4 million, reflecting a consistent product mix and cost structure. Operating losses for the entire year improved to $5.7 million, down from $6.8 million in the previous year, largely due to reduced selling, general and administrative expenses as well as lower research and development costs. The net loss for 2025 stood at $5.7 million, equivalent to $0.07 per share, marking a significant improvement compared to $4.7 million or $0.06 per share in 2024.

As of December 31, 2025, the company held $1.1 million in cash against $800,000 in debt, indicating a solid working capital position to support ongoing growth initiatives.

Strategic Initiatives

Milestone Scientific's strategic approach focuses on enhancing operational efficiency and expanding market presence. Under Eric Hines' leadership, the company has undergone a restructuring aimed at building a more capable commercial team and strengthening leadership. Key initiatives include:

• Increased Digital Marketing: The company ramped up targeted digital marketing efforts, which have already shown early traction in driving sales.
• Dental Ambassador Program: Launched in December and taken national in January, this program aims to increase engagement and sales through local ambassadors, predominantly dental hygienists. The goal is to generate a few hundred thousand dollars in new sales in 2026 from this initiative.
• International Expansion: Milestone is pursuing registrations for its dental products in key international markets, including Japan, India, and Mexico. While current guidance does not include revenue from these new markets, successful registrations could lead to additional growth opportunities.
• CompuFlo System Advancement: The company's CompuFlo system, designed for epidural injections, is expected to become a significant growth driver. The company relaunched its commercialization efforts in 2025, resulting in increased clinician interest and expanded reimbursement support to drive adoption. The introduction of the CompuFlo advisor program in February 2026 has further strengthened this initiative.

Future Outlook

Looking ahead, Milestone Scientific provided guidance for 2026, expecting total revenue to range between $9.8 million and $10.2 million, reflecting double-digit year-over-year growth. This growth is expected to be driven by increasing adoption across both the dental and medical markets. Notably, the CompuFlo system is projected to contribute between $500,000 and $600,000, representing an approximately 400% increase over 2025.

The company aims for improved operating leverage and a significant reduction in cash burn, thanks to cost actions implemented in 2025. The management's goal is to reach cash flow break-even by early 2027, a sharp focus that has been positively received by shareholders.

“Every cent that comes into this company is going to be used in the right way,” emphasized Eric Hines during the call, reflecting a commitment to shareholder value and sustainable growth.

Conclusion

In summary, Milestone Scientific, Inc. appears to be on a promising trajectory following its fourth quarter 2025 earnings call. The combination of disciplined financial management, strategic product launches, and a clear focus on growth initiatives positions the company well for the upcoming year. As it aims for cash flow break-even and expands into new markets, investors should watch closely for the implementation of these strategies and their impact on future performance. With a renewed operational model and ambitious goals for 2026, Milestone Scientific is set to enhance its market presence and deliver value to shareholders.